About the
Campaign About
Microbicides More Prevention
Options Trial
Ethics Community
Involvement GCM in
Action GC News
& Media GCM
Exhibit Download
Resources  

• Home
• About Microbicides

• More on Microbicides
• The Need
• How do they work?
• Testing & Trials

• More on Trials
• Trial Results

• iPrEx Trial Results Resources
• MDP 301: PRO 2000
• CAPRISA 004: Tenofovir Gel
• Resources about the CAPRISA 004 Trial and Results
• HPTN 035
• Webcasts from the AIDS 2010 Conference
• Carraguard Trials
• Cellulose Sulfate
• Nonoxynol-9

• Culture & Acceptability
• Advocacy

Home » About Microbicides » Testing & Trials » Trial Results » HPTN 035

HPTN 035

Promising News on Microbicides Trial Results

Results of the HPTN 035 Study

Last updated: 24th February 2009

On 9th February 2009, the US National Institutes of Health announced promising results of a multi-site clinical trial of two candidate microbicides. Known as HPTN 035, the trial evaluated the safety and effectiveness of BufferGel® and PRO 2000 (0.5 percent dose) for preventing male-to-female sexual transmission of HIV.

The trial found that women who were offered PRO2000 gel plus condoms had 30% fewer HIV infections than those offered only condoms or condoms plus a placebo gel. The other candidate microbicide tested, BufferGel, did not reduce HIV risk among women.

HPTN 035 Results Release Advocates Call Notes

Advocates' Frequently Asked Questions About HPTN 035
(Click here for the Word Version)

Click here to read GCM’s press release

Microbicides Trials Network (MTN)

MTN is an HIV/AIDS clinical trials network established in 2006 by the US National Institutes of Health.

Click on the links below to read:

MTN’s press release

MTN’s Questions and Answers Document

MTN’s fact sheet: HPTN 035 at a Glance

MTN’s Background paper on HPTN 035

National Institute of Allergy & Infectious Diseases

The NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses.

Click on the links below to read:

NIAID press release

NIAID Questions & Answers

Additional Resources:

16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)	Presentation on HPTN 035 Trial Results:"Safety and Effectiveness of Vaginal Microbicdies BufferGel and 0.5% PRO 2000/5 Gel for the Prevention of HIV Infection in Women: Results of the HPTN 035 Trial" (begin at slide #92) Highlight: South Africa’s Salim Abdool Karim’s section is of great interest to microbicide advocates
The Alliance for Microbicides Development	Click here to read the statement issued by the Alliance for Microbicides Development (AMD)
The International Partnership for Microbicides	Click here to read the statement issued by the International Partnership for Microbicides (IPM).

Media Highlights:

New pills, gel may prevent HIV in women	11th February - The Times of India, New Delhi
Gel Vaginal Contra el Sida Muestra Eficacia	11th February - Los Tiempos, Bolivia
New Gel Shows Promise in AIDS Fight	11th February - The Sydney Morning Herald, Australia
A glimmer of hope for microbicide research	10th February - PlusNews Global
Microbicide Gel May Help Against HIV	10 February - Meredith Wadman, Nature
Drugs Are Found to Block HIV in Monkeys	10 February - David Brown, Washington Post
Microbicide reduces HIV infections by 30% in first success for field	9th February, Gus Crains & Micheal Carter, AIDSMap
Novel HIV-Fighting Method Finally Gels	9 February - Jon Cohen, Science